However, as is often pointed out, increases in peroxisome proliferation and incidence of HCC have not been demonstrated in patients who take peroxisome proliferators long term [27], so we cannot say with certainty that PPARα contributes to the development of liver cancer in humans. This evidence concerns the gene PPARA and hepatocellular carcinoma.